SEC Form 4 · accession 0001203311-16-000169

SEATTLE GENETICS INC /WA · SGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Clay B Siegall

Officer — President and CEO · Director

Period of report

Nov 7, 2016

Accepted (ET)

Nov 9, 2016 · 7:16 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001060736

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Nov 7, 2016	M	2,442	$10.20	A	641,277	D
Common Stock^F3,F1	Nov 7, 2016	S	2,442	$57.4322	D	638,835	D
Common Stock^F1	Nov 7, 2016	M	1,600	$10.20	A	640,435	D
Common Stock^F4,F1	Nov 7, 2016	S	1,600	$56.5038	D	638,835	D
Common Stock^F1	Nov 7, 2016	M	7,113	$10.29	A	645,948	D
Common Stock^F5,F1	Nov 7, 2016	S	7,113	$59.2796	D	638,835	D
Common Stock^F1	Nov 7, 2016	M	3,310	$10.29	A	642,145	D
Common Stock^F6,F1	Nov 7, 2016	S	3,310	$58.2575	D	638,835	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F7	$10.20	Nov 7, 2016	M	2,442	D	—	May 25, 2017	Common Stock	2,442	25,849	D
Non-Qualified Stock Option (right to buy)^F7	$10.20	Nov 7, 2016	M	1,600	D	—	May 25, 2017	Common Stock	1,600	24,249	D
Non-Qualified Stock Option (right to buy)^F8	$10.29	Nov 7, 2016	M	7,113	D	—	Aug 28, 2017	Common Stock	7,113	97,107	D
Non-Qualified Stock Option (right to buy)^F8	$10.29	Nov 7, 2016	M	3,310	D	—	Aug 28, 2017	Common Stock	3,310	93,797	D

Explanation of responses

F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $57.06 to $57.78. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $56.05 to $57.05. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $58.79 to $59.78. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $57.78 to $58.76. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F7Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
F8Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.